

Stronger enhancer II/core promoter activities of hepatitis B virus isolates of B2 subgenotype than those of C2 subgenotype

Yanli Qin¹, Xueshi Zhou³, Haodi Jia⁴, Chaoyang Chen⁴, Weifeng Zhao³, Jiming Zhang^{1#} and Shuping Tong^{2, 4#}

¹Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; ²The Liver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA; ³Department of Infectious Diseases, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China; ⁴Key Lab of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Running head: Core promoter activities of HBV B2 vs. C2 genotype

Address correspondence to Jiming Zhang, M.D, Department of Infectious Diseases, Huashan Hospital, 12 Middle Wulumuqi Road, Shanghai 200040, China. Phone: +86 21 52888125. Fax: +86 21 62486140. Email: jmzhang@fudan.edu.cn; Shuping Tong, M.D.; Ph.D. Liver Research Center, Rhode Island Hospital, 55 Claverick Street, Providence, RI 02903, USA. Phone: 01-401-444-7365. Fax: 01-401-444-2939. Email: shuping_tong_md@brown.edu.

Y.Q. and X.Z. contributed equally to this work.

Supplementary Table. 1. Primers used to amplify HBV transcriptional regulatory elements and restriction sites used for cloning of PCR products.

| Regulatory elements | Primer | Sequence (5'-3')* | Position | Restriction site |
|----------------------------|---------------|---|-----------------|-------------------------|
| ENI+ENII | S1-a | TCGATC <u>TCGAGCTTCATGGGATATGTAATTGGGGTTG</u> | 876-898 | XhoI |
| | S1-b | TCGATC <u>TCGAGCTTCATGGGATATGTAATTGGAAG</u> | 876-898 | |
| | S1-c | TCGATC <u>TCGAGCTTCATGGGATATGTAATTGGGAG</u> | 876-898 | |
| | AS1 | <u>CACCCAAGGCACAGCTTGGG</u> AGCT CGAACAGT | 1857-1886 | SacI |
| ENI+ENII+CP | S2-a | TCGAT GAGCT <u>CCTTCATGGGATATGTAATTGGGGTTG</u> | 873-899 | SacI |
| | S2-b | TCGAT GAGCT <u>CCTTCATGGGATATGTAATTGGAAG</u> | 873-896 | |
| | S2-c | TCGAT GAGCT <u>CCTTCATGGGATATGTAATTGGGAG</u> | 873-896 | |
| | AS2 | <u>CACCCAAGGCACAGCTTGGG</u> AGCTT GAACAGT | 1871-1886 | HindIII |
| ENI | S3-a | TCGATA <u>GATCTCTTCATGGGATATGTAATTGGGGTTG</u> | 873-899 | BglII |
| | S3-b | TCGATA <u>GATCTCTTCATGGGATATGTAATTGGAAG</u> | 873-896 | |
| | S3-c | TCGATA <u>GATCTCTTCATGGGATATGTAATTGGGAG</u> | 873-896 | |
| | AS3 | <u>TATTGAGCT</u> CGCAGTATGGATCGGCAGAGGAG | 1276-1253 | SacI |
| ENII | S4 | CACTC <u>TCGAGCCTCTGCACGTCGCATGGA</u> | 1584-1612 | XhoI |
| | AS4 | <u>GACCAATTTATGCCTGGTAC</u> CTCC | 1798-1776 | KpnI |
| ENII+CP | S5 | <u>GAAACCACCGTGAGCT</u> CCCACC | 1611-1632 | SacI |
| | AS5 | CAAGGCACAGCTTGGG AGCTT GAAC | 1886-1862 | HindIII |

*underlined sequences are HBV specific. Restriction sites are in bold.